The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
JJ Cornelissen, A Gratwohl, RF Schlenk… - Nature reviews Clinical …, 2012 - nature.com
Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
[PDF][PDF] The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted …
JJ Cornelissen, A Gratwohl, RF Schlenk, J Sierra… - lucris.lub.lu.se
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is frequently applied as part
of treatment in acute myeloid leukemia (AML) in first or subsequent remission. It reduces …
of treatment in acute myeloid leukemia (AML) in first or subsequent remission. It reduces …
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
JJ Cornelissen, A Gratwohl… - Nature reviews …, 2012 - pubmed.ncbi.nlm.nih.gov
Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
[引用][C] The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted …
JJ Cornelissen, A Gratwohl, RF Schlenk… - Nat Rev Clin …, 2012 - portalrecerca.uab.cat
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for
patients with AML in remission: an integrated-risk adapted approach. — Universitat Autònoma …
patients with AML in remission: an integrated-risk adapted approach. — Universitat Autònoma …
[引用][C] The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted …
JJ Cornelissen, A Gratwohl, RF Schlenk… - Nature Reviews …, 2012 - cir.nii.ac.jp
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT
for patients with AML in remission: an integrated-risk adapted approach | CiNii Research …
for patients with AML in remission: an integrated-risk adapted approach | CiNii Research …
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: An integrated-risk adapted approach
J Cornelissen, A Gratwohl, R Schlenk… - Nature Reviews …, 2012 - repub.eur.nl
Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
JJ Cornelissen, A Gratwohl, RF Schlenk… - Nature Reviews …, 2012 - portal.research.lu.se
Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
JJ Cornelissen, A Gratwohl, RF Schlenk, G Sierra… - 2012 - med.muni.cz
Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.
JJ Cornelissen, A Gratwohl, RF Schlenk… - Nature reviews …, 2012 - europepmc.org
Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
[引用][C] The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted …
JJ Cornelissen, A Gratwohl, RF Schlenk, J Sierra… - 2012 - oparu.uni-ulm.de
ACUTE MYELOID-LEUKEMIA, STEM-CELL TRANSPLANTATION, ACUTE MYELOGENOUS
LEUKEMIA, VERSUS-HOST-DISEASE, MATCHED UNRELATED DONORS, BONE …
LEUKEMIA, VERSUS-HOST-DISEASE, MATCHED UNRELATED DONORS, BONE …